- Home
- ERAS vs CGC Comparison
ERAS vs CGC Comparison
Compare ERAS & CGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- CGC
- Stock Information
- Founded
- ERAS 2018
- CGC N/A
- Country
- ERAS United States
- CGC Canada
- Employees
- ERAS N/A
- CGC 960
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- CGC Pharmaceuticals and Biotechnology
- Sector
- ERAS Health Care
- CGC Health Care
- Exchange
- ERAS Nasdaq
- CGC Nasdaq
- Market Cap
- ERAS 439.7M
- CGC 427.4M
- IPO Year
- ERAS 2021
- CGC N/A
- Fundamental
- Price
- ERAS $2.32
- CGC $1.39
- Analyst Decision
- ERAS Buy
- CGC Hold
- Analyst Count
- ERAS 6
- CGC 1
- Target Price
- ERAS $3.83
- CGC N/A
- AVG Volume (30 Days)
- ERAS 1.7M
- CGC 23.5M
- Earning Date
- ERAS 11-11-2025
- CGC 11-07-2025
- Dividend Yield
- ERAS N/A
- CGC N/A
- EPS Growth
- ERAS N/A
- CGC N/A
- EPS
- ERAS N/A
- CGC N/A
- Revenue
- ERAS N/A
- CGC $201,572,742.00
- Revenue This Year
- ERAS N/A
- CGC $13.24
- Revenue Next Year
- ERAS N/A
- CGC $3.68
- P/E Ratio
- ERAS N/A
- CGC N/A
- Revenue Growth
- ERAS N/A
- CGC N/A
- 52 Week Low
- ERAS $1.01
- CGC $0.77
- 52 Week High
- ERAS $3.31
- CGC $5.80
- Technical
- Relative Strength Index (RSI)
- ERAS 68.53
- CGC 49.93
- Support Level
- ERAS $1.78
- CGC $1.33
- Resistance Level
- ERAS $2.65
- CGC $1.46
- Average True Range (ATR)
- ERAS 0.20
- CGC 0.10
- MACD
- ERAS 0.05
- CGC -0.00
- Stochastic Oscillator
- ERAS 68.34
- CGC 29.41
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About CGC Canopy Growth Corporation
Canopy Growth Corp, cultivates and sells medicinal and recreational cannabis and hemp through a portfolio of brands that include Doja, LivRelief, Ace Valley, Deep Space, and others. The Company is engaged in reportable segments namely: Canada cannabis, International markets cannabis, Storz & Bickel, and This Works. The company generates maximum revenue from Canadian cannabis.